We also identified specific biomarkers for classifying bladder cancer in two-tie grading system and found urinary measurement of Apo-A1 expression on independent series of urine samples served to distinguish not only patients with bladder cancer from controls, but also patients with low malignant BTCC from aggressive BTCC with high diagnostic accuracy. This evidence concerns the gene APOA1 and urinary bladder cancer.